Swiss company to appeal regulators’ decision.
Trials will resume once safety protocols have been reviewed.
Regulator drops demand for further phase 3 trial.
Cancer drugs from Novartis and Pfizer also backed
But analysts concerned over safety.
Lanadelumab could revolutionise treatment of swelling disease.
Biotech insists drug for rare inherited disorder is still approvable.
Could French biotech snap up remaining rights to pancreatic cancer drug?
Gaining access to ultra-orphan drugs could become much more difficult.